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Abstract: The molecular mechanisms of IgA nephropathy (IgAN) remain poorly understood. 
Several different polymorphic genes have been investigated in order to demonstrate their pos-
sible association with this disease. It is evident that mainly alternative and lectin pathways 
complement activation and play an important role in renal injury of IgAN. This study was 
conducted to determine eventual deficiencies of factor H in the SCR20 gene region and to look 
for a possible association between the polymorphism (+54) exon 1 of the MBL gene and the 
predisposition in Tunisian patients with IgAN. We then evaluated the effects of these FH muta-
tions and/or this MBL polymorphism on nephropathy susceptibility and progression. Polymor-
phism A/B (+54) in the exon1 of the MBL gene and analysis within the C-terminal domain of 
the protein SCR20 in the exon 22 of the factor H (FH) gene were conducted in 36 sporadic 
IgAN Tunisian patients and 117 age and gender matched healthy subjects recruited from blood 
donors, by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
and direct sequencing respectively. The analysis of the Gly54Asp (+54) mutation of the MBL 
gene according to the criteria of gravity of the IgAN reveals that the patients with genotype AB 
present more frequently with end-stage renal disease (ESRD) compared with those of genotype 
AA [OR: 8, CI (1.74–54.49), P = 0.019]. Moreover, the variant allele B was statistically more 
frequent than the allele A in patients with an association with initial arterial high blood pressure, 
ESRD and class V of the Haas classification compared to those without this association (P = 
0.009). The direct sequencing of exon 22 (SCR 20) of FH gene did not reveal any abnormal 
mutational deficiency for this factor in all patients and controls. The data did not support the 
hypothesis that FH is a susceptibility factor for the IgAN. However the data did show there 
was an association between AB (+54) exon1 MBL genotype and severe sporadic forms of this 
disease in Tunisian patients. Because of the small number of subjects studied, a much larger 
cohort of IgAN patients with varying severity of the disease and its progression would seem 
necessary to confirm these findings.
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Introduction
Immunoglobulin A nephropathy (IgAN) is the most prevalent form of primary glo-
merulonephritis and is an important cause of end-stage renal disease requiring renal 
transplantation. The molecular mechanisms of IgAN remain poorly understood. The 
environmental and genetic factors together with various inflammatory mediators were 
involved in the pathogenesis of IgAN.1
The mannose-binding lectin (MBL) gene is located on the long arm of chromosome 
10 at 10q11.2–q21 and contains 4 exons. Several functional polymorphisms of the MBL 
gene are localized in the region of the promoter and the exon 1have been described. International Journal of Nephrology and Renovascular Disease 2010:3 28
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The presence of any of mutant allele results in a significant 
reduction of serum MBL concentrations and have been 
reported,2–5 in particular codon 54 mutation of the MBL gene, 
has been found to be associated with recurrent infections and 
autoimmune diseases.6–8 MBL is a C-type lectin that has a 
high affinity to mannose. This protein takes part in natural 
immunity and it is known to active C4 and C2 without C1 
component, which is called “lectin pathway”.
The factor H (FH) is a 155 Kd soluble multiple-domain 
glycoprotein that it is abundant in human plasma. It regulates 
the alternative pathway (AP) activation of the complement 
system and it is a key molecular component of immune 
defense. The gene encoding FH is localized on the long arm 
of chromosome1 at 1q32, a locus called RCA (regulators 
of complement activation)9 which contains genes encod-
ing different regulatory proteins of complement activation. 
Primary sequence analysis of FH revealed a tandem array 
of 20 homologous units, called short consensus repeats 
(SCRs),10 each about 60 amino acid residues long. Conserved 
amino acid residues in the SCR unit include four cysteines 
that form disulfide bonds in a Cys1–Cys3 and Cys2–Cys4 
linkage. These disulfide bridges are important in maintaining 
the characteristic structure of the SCR module.11–13 Factor 
H controls amplification via the AP both in fluid phase and 
selectively on self-surfaces, thereby helping to direct comple-
ment toward its target: foreign or unwanted cells or particles. 
Via unknown mechanisms, FH competes with factor B for 
binding to C3b, accelerates the decay of C3 convertase and 
acts as a cofactor for factor I-mediated cleavage of C3b.14,16 
Low-resolution structural studies suggest a “beads-on-
a-string” arrangement of SCRs within an elongated FH 
molecule that may bend back on itself. The C3b-binding 
sites have been mapped to SCRs 1–4 and SCRs 19–20. The 
C-terminal C3b-binding site additionally binds polyanions 
on certain cellular surfaces, conferring to them resistance to 
damage as a consequence of AP activation.17,18
Mutations and polymorphisms in the regulator of comple-
ment activation, FH, have been linked to atypical hemolytic 
uremic syndrome,19 membranoproliferative glomerulonephri-
tis and recurrent meningococcal meningitis. The majority 
of these mutations are heterozygous and cause either single 
amino acid exchanges or premature translation interruption 
within the C-terminal domain of the protein SCR20.20
This study was conducted to determine eventual deficien-
cies of factor H in SCR20 gene region and to look for a pos-
sible association between the single nucleotide polymorphism 
(SNP) (+54) exon 1 of the gene MBL; and the predisposition 
in Tunisian patients with IgAN and to evaluate the effects of 
these FH mutations and/or this MBL polymorphism on this 
nephropathy susceptibility and progression.
Material and methods
Patients
A diagnostic of sporadic IgAN was assigned to 36 Tunisian 
patients (28 males and 8 females) by renal biopsy in the 
department of Nephrology, Charles Nicolle Hospital. The 
mean age was 35 ± 14 years and the mean disease duration 
at the time of the study was 5.54 ± 3 years. None of the 
patients had either clinical or laboratory evidence of Henoch-
Schoenlein purpura, liver or systemic disease. Patients were 
included in the study between August 2004 and March 2008. 
From all patients, clinical and laboratory data were obtained 
retrospectively. The criteria of severity of the disease were 
estimated for all patients; Haas histological classification, the 
presence of an initial arterial high blood pressure (HAP), as 
well as the renal function.
The glomerular filtration rate was estimated using the 
Cockcroft–Gault equation for creatinine clearance (eGFR). 
The renal function was considered normal when the (eGFR) 
was 60 mL minute 1.73 m2. The chronic renal failure (CRF) 
stage 1 to 5 was defined as follow as:
•    Stage 1: normal or relatively high eGFR (90 mL/minute/ 
1.73 m2) but presence of kidney damage (including abnor-
malities in blood or urine test or imaging studies).
•    Stage 2: mild reduction in eGFR (60–89 mL/minute/ 
1.73 m2) with kidney damage.
•    Stage 3: moderate reduction in eGFR (30–59 mL/minute/ 
1.73 m2).
•    Stage 4: severe reduction in eGFR (15–29 mL/minute/ 
1.73 m2) and preparation for renal replacement therapy.
•    Stage 5: established kidney failure (ESRD) (GFR  15 mL/
minute/1.73 m2) required permanent renal replacement 
therapy.
The Haas histological classification was defined as: sub-
class I, minimal or no mesangial hypercellularity, without glo-
merular sclerosis; subclass II, focal and segmental glomerular 
sclerosis without active cellular proliferation; subclass III, 
focal proliferative GN; and subclass IV , diffuse proliferative 
GN; and subclass V , any biopsy showing  or = 40% globally 
sclerotic glomeruli and/or  or = 40% estimated cortical 
tubular atrophy or loss,
Controls
As a control group, we studied 117 age and gender matched 
healthy subjects recruited from the blood donors of the same 
area as the patients.International Journal of Nephrology and Renovascular Disease 2010:3 29
Genetic polymorphisms in factor H and MBL genes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The study was approved by the local ethics committee 
and informed consent was obtained from all subjects.
Methods
Complement assays
Freshly drawn ethylene diamine tetraacetic acid (EDTA) 
plasma samples were obtained from all patients.
Functional CH50 levels were measured by the method 
of Mayer21 and expressed in units CH50/mL.
Functional alternative pathway activity (AP50) was mea-
sured in agarose plates, using 0.5% guinea pig erythrocytes 
suspended in 1% agarose made with veronal buffered saline, 
pH:7.4, 0.01M ethylene glycol tetraacetic ac (EGTA) and 
0.005 M Mg2+. Results were expressed as a percentage of 
mean values obtained with reference plasma prepared from 
100 healthy blood donors (normal range, 100% ± 30%).
Plasma concentrations of the third (C3) and/or fourth 
(C4) complement component and Factor B (FB) antigens 
were measured by nephelometry (Minineph™, The Binding 
Site, Birmingham, UK). Normal values established with 
pooled plasma from 100 healthy donors ranged 1,21 ± 0,36, 
0,26 ± 0,12 and 0,20 ± 0,11 g/l, respectively. Plasma levels 
of the C3 and/or C4 below the lower limit of normal ranges, 
defined as mean ± 1 standard deviation (SD), were taken to 
indicate hypocomplementemia.
Serum samples were used to quantify FH antigen concen-
tration by radial immunodiffusion (RID) assay using com-
mercially available kits (The Binding Site, Birmingham, UK). 
Results of the RID method were confirmed by enzyme-linked 
immunosorbent assay (ELISA) assay, described previously 
by Dragon-Durey,23 using a mouse anti-human FH mono-
clonal antibody (Serotec, Fidlington, UK). Normal ranges 
were 100% ± 30%, as calculated by the results from 100 
individual healthy donors.
Genomic FH DNA sequencing
Analysis of the FH gene was performed using DNA extracted 
from 10 mL peripheral EDTA blood using the standard 
salting-out procedure.22 Genomic DNA was amplified by 
means of polymerase chain reaction (PCR) using nucleotides 
flanking each exon.
All patients and controls were analyzed for SCR20 
exon 22, using primer designed on published genomic 
sequences: 5′CGA ACC TCA TTT TCA CAT CGA3′ (For-
ward primer) and 5′AAC CGT TAG TTT TCC TGG ATT 
TAA 3′ (Reverse primer).23
The PCR reactions were performed in 20 ul final volume 
using 10 pmol of each primer and containing 100 ng of 
extracted DNA, 0.5 U of Taq polymerase (Promega, USA), 
1.5 mM MgCl2 and 0.2 mMol/l dNTP (deoxynucleotide 
triphosphate). After an initial denaturing time of 5 minutes 
at 94°C, PCR reactions were run for 30 cycles including 30 
seconds at 94°C, 45 seconds at 60°C and 45 seconds at 72°C, 
with a final extension at 72°C for 7 minutes. PCR products 
were purified using QIAquick™ PCR purification kit (Qia-
gen, Hilden, Germany). Direct sequencing of the purified 
PCR products was then carried out by the dye terminator 
cycle sequencing method (Applied Biosystems, Courta-
boeuf, France) using a ABI prism 310 sequencer (Applied 
Biosystems). Sequence analyses were performed using the 
Sequencher® software, (Ann Arbor, MI, USA). The number 
of nucleotides or codons referenced is indicated according 
to Warwicker and colleagues.24,25
Polymorphism A/B (+54) 1  
of the gene MBL
The Gly54Asp mutation at codon 54 of gene MBL was 
analyzed by polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP).
The PCR reactions were performed in 50 ul final volume 
using 10 pmol of each primer: 5′AGTCGACCCAGATT-
GTAGGACAGAGA 3′, forward primer and 5′AGGATC-
CAGGCAGTTTCCTCTGGAAGG 3′, reverse primer, 
and containing 200 ng of extracted DNA, 1 U of Taq 
polymerase (Promega, USA), 1,5 mM MgCl2 and 0.2 mMol/l 
dNTP. After an initial denaturing time of 2 min at 94°C and 5 
min at 72°C; PCR reactions were run for 35 cycles including 
30s at 94°C, 1 min at 55°C and 2 min at 72°C, with a final 
extension at 72°C for 5 min. The PCR products obtained 
were 349 bp and were digested by 1 U of the enzyme BanI 
(Promega, Madison, WI, USA) at 37°C for 2 hours and 
then subjected to electrophoresis in 3% agarose gel stained 
with ethidium bromide. The PCR generated two fragments 
of 260 and 89 bp for A allele and one fragment of 349 bp 
for B allele.
Statistical analysis
Allelic and genotypic frequencies were evaluated by direct 
counting. Statistical comparisons were performed, between 
patients and controls, by Pearson’s chi-square test calculated 
on 2 × 2 contingency tables. A Fisher exact test was used 
when an expected cell value was less than 5. P value  0.05 
was considered to be statistically significant. Statistical 
power was calculated using a web power calculator (http://
calculators.stat.ucla.edu/powercalc/). The strength of the 
association of MBL (+54) genotypes as genetic factor with International Journal of Nephrology and Renovascular Disease 2010:3 30
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the frequency of a certain IgAN symptom was estimated by 
the calculation of the Odds ratios (OR) (OR  1: positive 
association; OR = 1: no influence; OR  1: protective) and 
95% confidence intervals (95% CI), using the same software. 
The Mann-Whitney U test was used to determine whether 
there was any significant difference between MBL genotype 
groups for continuous data.
Results
Clinical characteristics
At the time of this study, among 36 patients, 12 (33.33%) 
had severe histological lesions, 24 (66.66%) had an initial 
arterial high blood pressure (HAP), 14 (38.88%) were in CRF 
and 10 (27.77%) were in ESRD. Six IgAN patients had an 
association between three criteria of severity disease: HAP, 
class V of Haas classification and ESRD.
Complement component assessment
The mean C3 concentration was 1.31 g/L (range 0.90–1.72) 
and C4 was 0.41 g/L (range 0.26–0.56). Five patients had 
low C3 levels of 0.90 g/L (0.77, 0.27, 0.80, 0.84 and 0.86 g/L 
respectively) and eight had low C4 levels (0.24, 0.25, 0.23, 
0.24, 0.20, 0.12, 0.22 and 0.17 g/L respectively). None of 
patients had low factor H level (Table 1).
Polymorphism A/B (+54) exon 1 of the 
gene MBL
The genotypic and allelic frequencies of SNP (A/B) at the 
codon 54 of the gene MBL do not show statistically sig-
nificant differences between the patients and the controls 
(Table 1). The analysis of this polymorphism, according to 
the criteria of gravity of the IgAN, reveals that the patients 
of genotype AB present more frequently as ESRD com-
pared with those of genotype AA [OR: 8, CI (0.90–86.17), 
P = 0.038]. Moreover, among the 6 patients carrying three 
severity criteria of IgAN disease (HAP, class V of Haas clas-
sification and ESRD), 4 (66.6%) had the genotype A/B. So, 
the allele B was statistically more frequent than the allele A 
in patients with this association compared to those without 
it (P = 0.009) (Table 2). Nevertheless, there was no statisti-
cally significant correlation between this variant allele B 
and low levels of C3 and/or C4 observed in study patients 
(data not shown).
Genetic HF genotyping
The direct sequencing of exon 22 (SCR 20) gene of this 
protein did not reveal mutational deficiency abnormalities 
for this factor in all patients and controls.
Table 1 Clinical, biological, histological and genetic characteristics 
of IgAN patients
Patient 
number
Initial 
HAP
Haas clas-
sification 
stage
Renal 
function
C3 level 
(g/l)
C4 level 
(g/l)
Genotype 
MBL
1 No II Normal 1,685 0,246 AA
2 No II Normal 1,327 0,41 AA
3 Yes V CRF 1,004 0,588 AA
4 No II Normal 1,280 0,569 AA
5 Yes V CRF 1,027 0,424 AA
6 Yes III ESRD 1,655 0,443 AA
7 No III Normal 1,006 0,383 AA
8 Yes V CRF 1,327 0,255 AA
9 No II Normal 1,532 0,874 AA
10 Yes V ESRD 1,616 0,587 AB
11 Yes V ESRD 1,172 0,274 AA
12 Yes V CRF 1,090 0,373 AA
13 Yes V ESRD 0,777 0,601 AB
14 Yes II CRF 1,376 0,488 AA
15 Yes V ESRD 1,853 0,237 AA
16 Yes IV Normal 0,275 0,481 AA
17 Yes V ESRD 1,229 0,33 AB
18 Yes III Normal 0,802 0,416 AA
19 Yes III CRF 1,033 0,529 AA
20 Yes III CRF 0,843 0,398 AA
21 No V ESRD 0,864 0,409 AA
22 No V Normal 0,889 0,374 AA
23 Yes III CRF 1,067 0,241 AA
24 No II CRF 1,974 0,467 AA
25 Yes II ESRD 1,135 0,4 AA
26 Yes III CRF 1,777 0,291 AA
27 Yes II CRF 1,470 0,402 AA
28 No II Normal 1,168 0,2 AA
29 No IV CRF 1,154 0,475 AA
30 Yes V ESRD 1,582 0,505 AB
31 Yes I CRF 1,953 0,122 AA
32 No I Normal 2,159 0,351 AB
33 No II Normal 2,066 0,637 AA
34 Yes I CRF 1,684 0,539 AA
35 Yes IV ESRD 0,980 0,52 AA
36 Yes III Normal 1,397 0,226 AB
Notes: Normal: the renal function was considered normal when the (eGFR) 
was 60 mL minute/1.73 m2. CRF: the chronic renal failure includes stage 2 to 4: ESRD, 
established kidney failure (stage 5: eGFR  15 mL/minute/1.73 m2).
Discussion
It is currently established that activating or regulating comple-
ment proteins plays a role in the renal injury of the IgAN.26 
MBL is the key protein of the activation of the complement 
by the lectin pathway. This activation originate with the International Journal of Nephrology and Renovascular Disease 2010:3 31
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deposition of MBL in the renal glomerular mesangial area, 
and co-localized with IgA, in about 20% of IgAN patients.8 
Furthermore, Roos and colleagues found the same deposition 
in IgAN patients who had severe renal histological lesions and 
with the severe clinical forms of the disease.27,28 Mesangial 
cell proliferation was also marked in MBL-positive patients. 
In addition, MBL deficiency and low serum levels are strongly 
associated with the presence of MBL alleles that encode three 
different structural variants of MBL polypeptide (codon 52, 
54 and 57). Among these variants at the exon1, Gly54Asp is 
the most important cause in the reduction of the serum MBL 
levels.5 Several different polymorphic genes have been inves-
tigated in order to demonstrate their possible association with 
IgAN susceptibility and progression, as HLA-DQ, cytokines 
which are associated with the inflammatory response (tumor 
necrosis factor [TNF], interleukin 1 [IL1]) or Fc α receptor 
(CD89).29–32 These studies have shown conflicting results 
and it may be postulated that genetic factors vary among 
different populations. This is in conflict with the reported 
results by Pirulli and colleagues,33 because in our study, the 
analyzed polymorphism of the MBL gene did not appear to 
be involved in the susceptibility of IgAN. Nevertheless, the 
analysis of the clinical, histological and biological character-
istics of the patients reveals a positive association between 
the variant allele B and the severe forms of the renal disease 
with class V histological of Haas, ESRD and an initial HAP 
in Tunisian patients. However, the wide CI in many of these 
analyses reflects the relatively small numbers in some of the 
subgroups, with a consequent loss of statistical power. A 
larger patient cohort would therefore be required for us to 
reduce the width of the CI and confirm these observations. 
Indeed, the calculation of the required sample size for 80% 
statistic power and two-sided significance level (alpha): 0.05 
estimates a sample of 479 patients and controls. More stud-
ies are needed to clarify if the determination of patients’ 
MBL genotypes could be a useful prognostic factor in IgAN 
clinics.
The other complement genes might be acting as suscepti-
bility factors for IgAN. There have been reports of deficiency 
and mutations in the serum complement regulator factor H 
in association with IgAN. Filler and colleagues34 reported a 
mutation in FH exon 23 in a patient with evidence of mesan-
gial IgA deposition in the presence of histological features 
of membranoproliferative glomerulonephritis. In atypical 
hemolytic uremic syndrome (aHUS), the majority of the 
mutations described to date cluster in FH exons 18–23 are 
usually associated with impaired secretion of FH, in particular 
those localized within the C-terminal domain of the protein 
SCR20. In our study we elected to investigate only this one 
region by direct sequencing. There was no significant differ-
ence between patients and controls. In all patients, none were 
found to have a low level of FH concentration. Our cohort 
was small and it is possible that it is underpowered. In accord 
with our findings, Edey and colleagues35 screened FH exons 
18–23 in IgAN patients and found no abnormalities.
In conclusion our study has not found evidence to support 
the hypothesis that FH is a susceptibility factor for the IgAN, 
and yet does show an association between A/B (+54) exon1 
MBL genotype and severe sporadic forms of this disease in 
Tunisian patients. However, because of the small number of 
subjects studied, these results must be treated with caution. 
A much larger cohort of IgAN patients with varying severity 
of the disease and its progression would seem necessary to 
confirm these findings.
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